<DOC>
	<DOCNO>NCT00214253</DOCNO>
	<brief_summary>Our hypothesis successful clinical islet transplant program establish University Wisconsin use steroid -free , sirolimus- low dose tacrolimus - base immunosuppressive drug regimen ( Edmonton protocol ) . We intend answer follow research question : 1 ) treatment islet transplant recipient thiazolidinediones ( i.e . pioglitazone ) enhance post-transplant islet function reduce number islet necessary achieve adequate metabolic control ? 2 ) type 1 diabetic patient optimal candidate islet transplantation ( i.e . islet transplant alone islet kidney transplantation ) ? 3 ) Can cadaver donor pancreas , ordinarily discard use pancreas transplantation use islet transplantation ?</brief_summary>
	<brief_title>Islet Transplantation Type 1 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>16 Type I insulindependent diabetic subject age 1860 , ( 8 receive prior kidney liver transplant stable renal function , 8 labile glucose regulation fail trial intensive exogenous insulin therapy preserve native renal function ) untreated proliferative diabetic retinopathy ; HgbA1C &gt; 12 % ; creatinine clearance &lt; 80 ml/minute macroalbuminuria &gt; 0.3 gm/24 hr ; presence panel reactive antibody &gt; 20 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>